Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P62306
UPID:
RUXF_HUMAN
Alternative names:
Sm protein F
Alternative UPACC:
P62306; A2VCR2; B2R498; Q15356; Q6IBQ1; Q6P4I0
Background:
Small nuclear ribonucleoprotein F (Sm protein F) is a core component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs), essential for pre-mRNA splicing. It participates in the formation of both the pre-catalytic spliceosome B complex and activated spliceosome C complexes, playing a critical role in the splicing of U12-type introns and histone 3'-end processing.
Therapeutic significance:
Understanding the role of Small nuclear ribonucleoprotein F could open doors to potential therapeutic strategies.